RESULTS	Of the respondents who chose the less expensive test , 40 % indicated that they did not believe that the patient in the scenario was at significant risk for cancer , 13 % indicated that they thought the less expensive test was adequate or not meaningfully different from the more expensive test , 12 % thought the cost of the test was not worth the additional benefit , 9 % indicated that the test was too expensive ( without mention of additional benefit ) , and 7 % responded that resources were limited .\